BioLife appoints Cathy Coste to board as director and audit committee chair

BIOLIFE SOLUTIONS INC

Effective March 18, 2025, Catherine Coste appointed to board, replacing Joydeep Goswami as audit committee chair.
Coste brings over 30 years at Deloitte as senior partner and life sciences industry leader.
She will serve until 2025 Annual Meeting and receive standard non-employee director compensation.
Board expanded to seven members; Coste independent under SEC and Nasdaq rules.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Catherine Coste

Director and Audit Committee Chair

BLFS · BIOLIFE SOLUTIONS INC

Effective: 2025-03-18
Filed: March 24, 2025, 7:59 PM ET

Effective March 18, 2025, the board of directors (the “Board”) of BioLife Solutions, Inc. (the “Company”) appointed Catherine Coste to serve as a member of the Board until the Company’s 2025 Annual Meeting of Stockholders

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Catherine Coste was appointed as Director and Audit Committee Chair at BIOLIFE SOLUTIONS INC.

Action: appointed
Role: Director and Audit Committee Chair

Exact text from the filing

Effective March 18, 2025, the board of directors (the “Board”) of BioLife Solutions, Inc. (the “Company”) appointed Catherine Coste to serve as a member of the Board until the Company’s 2025 Annual Meeting of Stockholders

View on SEC.gov

BIOLIFE SOLUTIONS INC filing history →

Source: SEC EDGAR

accession 0001628280-25-014541

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.